Expansion of CSL Biotech facility drives advanced manufacturing growth
The development will help meet growing global demand for albumin.
CSL has officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.
The facility is an important addition to the Australian pharmaceutical manufacturing landscape and is expected to produce therapies with an estimated annual market value of $850 million, as well as generate up to 200 new jobs by 2026.
The development, which received significant support from the Victorian Government, will help meet growing global demand for albumin – a protein derived from human plasma that is used in critical care to treat burns and shock.
The world-class plant will be constructed over two modules, with today’s opening marking the completion of module one. The module will expand albumin production on the site to 100 tonnes per annum. When it comes online, module two will add a further 100 tonnes in capacity.
When fully operational, the facility will export product to the US and Europe while also producing commercial product for the local Australian and Asia Pacific markets.
“CSL’s investment in Broadmeadows embeds the site into our global plasma manufacturing supply chain, which now supplies lifesaving therapies to patients in more than 60 countries,” said CSL’s CEO, Paul Perreault.
He also gratefully acknowledged the Victorian Government’s support: “State Government support for this project helped secure the facility for Broadmeadows and was contingent on our meeting agreed project milestones and employment outcomes.”
Minister Carroll said: “This project will bring new advanced manufacturing jobs to Broadmeadows and help sustain the 1000 highly skilled jobs already on this site. This facility is a great example of the sort of advanced manufacturing that can help drive economic growth in Victoria.”
The Hon. Philip Dalidakis, Minister for Trade & Investment, Innovation & the Digital Economy and Small Business, said: “This is yet another example of an innovative company investing in Victoria to support our economy and create jobs, and we look forward to continuing to work with CSL well into the future.”
The Broadmeadows site has played a key role in CSL’s expansion strategy with over $610 million invested in the site in the past 5 years. The site opened a Biotechnology Manufacturing Facility in May 2014, for the large-scale manufacture of novel recombinant therapies for international clinical trials, and in December 2015 opened the Turner Facility for the manufacture of a therapy to treat immune disorders.
The Broadmeadows site is home to Australia’s only plasma manufacturing facility and the only commercial-scale facility of its type in the Southern Hemisphere.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance